Massimo Imazio
Sheba Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Massimo Imazio.
Circulation | 2008
Alon Eisen; Alexander Tenenbaum; Nira Koren-Morag; David Tanne; Joseph Shemesh; Massimo Imazio; Enrique Z. Fisman; Michael Motro; Ehud Schwammenthal; Yehuda Adler
Background— Calcification of the thoracic aorta is associated with atherosclerotic risk factors, yet its pathogenesis and clinical implications are not yet elucidated. The goal of the present study was to assess whether thoracic aorta calcification is associated with an increased risk of cardiovascular events and death in patients with stable angina pectoris. Methods and Results— A prospective cohort of 361 stable angina pectoris patients (307 men, 54 women; age range, 37 to 83 years) underwent chest spiral computed tomography and were evaluated for aortic calcification. We recorded the incidence of cardiovascular events and death during a 4.5- to 6-year follow-up. Aortic calcification was documented in 253 patients (70% of patients; 213 men, 40 women). Patients with aortic calcification were older (mean age, 65±7 versus 55±9 years; P<0.001), and fewer were classified as smokers (13% versus 26%; P=0.014) compared with patients without aortic calcification. Significant correlation was found between patients with and those without aortic calcification for the presence of aortic valve calcification (28% versus 11%; P<0.001), mitral annulus calcification (29% versus 4%; P<0.001), and coronary calcification as expressed by coronary calcium score. (P<0.001). During 4.5 to 6 years of follow-up, 19 patients died, all of whom were in the aortic calcification group. Age-adjusted hazard ratios for total events and cardiovascular events by aortic calcification were 2.84 (95% CI, 1.52 to 5.30; P=0.001) and 2.70 (95% CI, 1.33 to 5.47; P=0.006), respectively. In multivariable analysis, hazard ratios for total events and cardiovascular events were 2.79 (95% CI, 1.46 to 5.20; P=0.002) and 4.65 (95% CI, 1.19 to 18.26; P=0.028), respectively. Conclusions— Calcification of the thoracic aorta is age related and associated with coronary calcification and valvular calcification. Thoracic aortic calcification is associated with an increased risk of death and cardiovascular disease.
International Journal of Clinical Practice | 2010
Massimo Imazio; David H. Spodick; Antonio Brucato; Rita Trinchero; Gal Markel; Yehuda Adler
Aims:u2002 To review the current major diagnostic issues on the diagnosis of acute and recurrent pericarditis.
The Cardiology | 2013
I. Burazor; Massimo Imazio; Gal Markel; Yehuda Adler
Malignant pericardial effusion is a common and serious manifestation in malignancies. The origins of the malignant process include solid tumors or hematological malignancies, while primary neoplasms of the pericardium are less common. In the oncological patient, pericardial effusion may develop by several different mechanisms, namely by direct or metastatic spread of the primary process or as a complication of antineoplastic therapies. In some cases, pericardial effusion may be the first manifestation of the disease, and that is why malignancy must be excluded in every case of an acute pericardial disease with cardiac tamponade at presentation, rapidly increasing pericardial effusion and an incessant or recurrent course. Thus, the definite differentiation of malignant pericardial effusion and rapid diagnosis are of particular therapeutic and prognostic importance. Management of these patients is multidisciplinary and requires team work, but at present there is a need for further research. An individual treatment plan should be established, taking into account cancer stage, the patients prognosis, local availability and experience. In emergency cases with cardiac tamponade or significant effusion, initial relief can be obtained with pericardiocentesis. Despite the magnitude of this serious problem, little progress has been made in the treatment of pericardial effusion secondary to malignant disease.
Circulation | 2000
Massimo Imazio; Riccardo Belli; Franco Pomari; Enrico Cecchi; Alessandra Chinaglia; Gianni Gaschino; Aldo Ghisio; Rita Trinchero; A. Brusca
A 28-year-old man was admitted to the Emergency Department for syncope after several hours of violent vomiting and diarrhea. A few minutes after arrival, he complained of palpitations followed by a sudden loss of consciousness. An ECG showed a polymorphic ventricular tachycardia degenerating into ventricular fibrillation (Figure 1⇓). Because of recurrent major ventricular arrhythmias, resuscitation was necessary for 1 hour. The patient was eventually admitted to the Coronary Care Unit. Physical examination, ECG (Figure 2⇓), chest x-ray, …
Journal of Cardiovascular Medicine | 2014
Massimo Imazio; Riccardo Belli; Federico Beqaraj; Massimo Giammaria; Chiara Lestuzzi; Brian Hoit; Martin LeWinter; David H. Spodick; Yehuda Adler
Objectives Evidence to support the use of pericardial drainage instead of simple pericardiocentesis for nonmalignant pericardial effusions refractory to medical therapy is based on observational studies and experts’ opinions, rather than randomized trials. The aim of the present trial is to fill this knowledge gap and to provide a stronger base of evidence to support a specific interventional treatment in this setting. Methods DRainage Or Pericardiocentesis (DROP) alone for recurrent nonmalignant, nonbacterial pericardial effusions requiring intervention is a randomized, open-label and multicenter study. The primary efficacy endpoints are the incidence of recurrent pericardial effusion, and the need for additional pericardiocentesis or cardiac surgery at 12 months. Secondary endpoints are hospital length stay, disease-related admission and overall mortality. Safety and complications rates of each intervention will be also assessed. Implications and conclusion The DROP trial will be the first multicenter randomized trial to evaluate the efficacy and safety of pericardiocentesis versus pericardiocentesis and extended pericardial drainage for recurrent nonmalignant, nonbacterial pericardial effusions refractory to medical therapy and requiring interventional treatments (ClinicalTrials.gov Identifier: NCT01665495).
Российский кардиологический журнал | 2016
Yehuda Adler; Philippe Charron; Massimo Imazio; Luigi P. Badano; Gonzalo Barón-Esquivias; Jan Bogaert; Antonio Brucato; Pascal Gueret; Karin Klingel; Christos Lionis; Bernhard Maisch; Bongani M. Mayosi; Alain Pavie; Arsen D. Ristić; Manel Sabaté Tenas; Petar Seferovic; Karl Swedberg; Witold Tomkowski; Е. О. Таратухин; Г. П. Арутюновым
The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS)
Archive | 2016
Dor Lotan; Yishay Wasserstrum; Massimo Imazio; Yehuda Adler
Archive | 2016
Massimo Imazio; Luigi P. Badano; Bernhard Maisch; Bongani M. Mayosi; Alain Pavie; Arsen D. Risti; Witold Tomkowski; Yehuda Adler
Archive | 2015
Yehuda Adler; Philippe Charron; przewodniczący; Massimo Imazio; Luigi P. Badano; Jan Bogaert
Archive | 2015
Yehuda Adler; Philippe Charron; Massimo Imazio; Luigi P. Badano; Bernhard Maisch; Bongani M. Mayosi; Alain Pavie; Arsen D. Ristić